• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE; PROSTHESIS, MITRAL VALVE, PERCUTANEOUSLY DELIVERED

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

EDWARDS LIFESCIENCES EDWARDS SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE; PROSTHESIS, MITRAL VALVE, PERCUTANEOUSLY DELIVERED Back to Search Results
Model Number 9750TFX
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Mitral Valve Insufficiency/ Regurgitation (4451)
Event Date 04/01/2022
Event Type  Injury  
Manufacturer Narrative
This report provides data from thv/tvt registry exemption number e2016006 and summarizes 1 reintervention - mitral valve event for the sapien 3 ultra transcatheter heart valve in the mitral position.The ''time to event'' (tte, in days) for this event was 156.The device identification (di) numbers for edwards sapien 3 ultra transcatheter heart valve are: (b)(6).Intra-procedural and in hospital mitral valve re-intervention will typically result from valve malposition or regurgitation (pvl or central, including leaflet restriction).These conditions are known potential risks associated with the use of the thv, delivery system, and/or accessories.There are multiple patient and procedural factors that alone or in combination can cause or contribute to valve malposition, including improper positioning prior to deployment, poor image intensifier angle, poor coaxial alignment of the valve and delivery system, characteristics of the pre-existing valve or ring, loss of pacing capture, rapid deployment, release of stored tension during deployment, and movement of the delivery system by the operator.Valve malposition has the potential to contribute to suboptimal coaptation of the thv valve leaflets and cause central aortic insufficiency; it can lead to migration or embolization of the prosthesis.Physicians are extensively trained by edwards before they are qualified to use the thv.Training includes patient screening, device preparation, approach, deployment, imaging, procedure-specific training manuals and proctored procedures.The correct alignment and positioning of the device at the point of deployment is emphasized as a key factor to the placement and fixation of the device.Operators are also instructed to use fluoroscopy as the primary method of visualization for positioning and deployment.In this case, specific procedural details are not available to determine potential contributing factors.The ifu and training manuals have been reviewed and no inadequacies have been identified with regards to warnings, contraindications, and the directions/conditions for the successful use of the device.Complaint histories for all reported events are reviewed against trending control limits on a monthly basis, and any excursions above the control limits are assessed and documented as part of this monthly review.No corrective or preventative actions are required.H3 other text : summary report.
 
Event Description
Thv/tvt registry summary reporting for adverse event submission for quarter 2 2022 data extract for mitral serious injury events for the sapien 3 ultra valve.This report summarizes 1 reintervention - mitral valve event for the sapien 3 ultra transcatheter heart valve.
 
Manufacturer Narrative
Correction to the exemption number field per fda request on 07/07/2022.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EDWARDS SAPIEN 3 ULTRA TRANSCATHETER HEART VALVE
Type of Device
PROSTHESIS, MITRAL VALVE, PERCUTANEOUSLY DELIVERED
Manufacturer (Section D)
EDWARDS LIFESCIENCES
1 edwards way
irvine CA 92614
Manufacturer Contact
renee van dorne
1 edwards way
irvine, CA 92614
9492506385
MDR Report Key14894483
MDR Text Key295229420
Report Number2015691-2022-06596
Device Sequence Number1
Product Code NPU
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P140031
Exemption Number2016006
Number of Events Reported1
Summary Report (Y/N)Y
Report Source Manufacturer
Source Type Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial,Followup
Report Date 07/26/2022
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/01/2022
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number9750TFX
Device Catalogue NumberN/A
Device Lot NumberN/A
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received07/07/2022
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age72 YR
Patient SexFemale
-
-